trial · primary record
Guselkumab
Fistulizing Crohns Disease
| Phase | Phase 3 |
|---|---|
| Status | ACTIVE |
| Sponsor | Unknown |
| Enrolment | 288 |
| Primary completion | 2027-03-25 |
| Primary endpoint | Percentage of Participants who Achieve Combined Fistula Remission at Week 24 |
| Registry ID | NCT05347095 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-11-04T03:54:56.538Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT05347095
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.
Same entity, elsewhere in the suite
- Guselkumab · approval
- Guselkumab · compound